CSPC Pharmaceutical Group Limited 1093

Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.

Non-small cell lung cancer is increasingly evolving into a biomarker-driven market, with EGFR-mutated disease emerging as one of the most commercially significant segments. The space is dominated by blockbuster EGFR-targeted therapies such as TAGRISSO, which now generates nearly USD 6 billion annually, reinforcing the importance of precision medicine in NSCLC management.

CSPC Pharmaceutical Group (SEHK:1093) has received regulatory approval in China to start clinical trials for its new antibody drug conjugate SYS6051. The therapy targets advanced solid tumors and has been cleared as a Class 1 biological drug candidate. The approval allows the company to begin clinical evaluation of SYS6051 across a broad range of advanced cancers. CSPC Pharmaceutical Group, a major player in China's pharmaceutical sector, has been building out its oncology pipeline...

Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with albumin-bound Docetaxel for Injection (HB1801) from CSPC as neoadjuvant treatment of breast cancer, have been

Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with Docetaxel for Injection (Albumin-bound) (HB1801), has met the pre-specified primary endpoint of total pathological complete response (tpCR) in a Phase III clinical study (KN026-004) f

The Board of Directors of CSPC Pharmaceutical Group announced it has received approval from China's National Medical Products Administration to begin clinical trials for SYH2061 Injection, an ultra-long-lasting siRNA drug that targets complement component C5 for treating IgA nephropathy and other complement-mediated diseases. This marks the first independently developed siRNA drug targeting C5 to advance to clinical trials in China, highlighting CSPC's expanding capabilities in innovative...

Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 millionAs of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion as of Sept. 30, 2025Company to host conference cal

The Board of Directors of CSPC Pharmaceutical Group recently announced that its novel SYH2070 siRNA injection received regulatory approval to begin clinical trials in both the U.S. and China for the treatment of hypertriglyceridemia and mixed hyperlipidemia. This dual approval marks a significant milestone in CSPC’s pipeline of innovative therapies, highlighting the global interest in next-generation siRNA drug candidates targeting ANGPTL3. We'll examine how gaining international clinical...